eTheRNA CEO outlines development plan in cancer RNA space

November 24, 2016 Christoph Graener

Mike Ward, global director of content for Informa Pharma Intelligence, interviews Dirk Reyn, CEO of eTheRNA, on the sidelines of the BIO-Europe® partnering conference in Cologne, Germany. The pair discusses eTheRNA’s emerging cancer immunotherapy pipeline, funding prospects and the next steps for the company—which was founded in 2013—as it looks to expand its business.

  

  

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Dirk Reyn – President and CEO, eTheRNA

 

Previous Article
Peter Fong on Genentech’s science shopping list, recent BioNtech deal
Peter Fong on Genentech’s science shopping list, recent BioNtech deal

Peter Fong explains Genentech's oncology focus, seeking the best science and how a typical biotech deal wor...

Next Article
Freshly-appointed Auspherix CEO highlights new antibiotic class
Freshly-appointed Auspherix CEO highlights new antibiotic class

Auspherix’s newly-appointed CEO talks about the science behind the company’s gram-negative targeting new an...